



## Eagle Pharmaceuticals to Discuss First Quarter 2019 Financial Results on May 7, 2019

April 29, 2019

WOODCLIFF LAKE, N.J.--([BUSINESS WIRE](#))--Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2019 first quarter financial results on Tuesday, May 7, 2019, before the market opens.

Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date	Tuesday, May 7, 2019
Time	8:30 a.m. EDT
Toll free (U.S.)	877-876-9176
International	785-424-1670
Webcast (live and replay)	<a href="http://www.eagleus.com">www.eagleus.com</a> , under the "Investor Relations" section

A replay of the conference call will be available for one week after the call's completion by dialing 800-839-5493 (US) or 402-220-2552 (International) and entering conference call ID EGRXQ119. The webcast will be archived for 30 days at the aforementioned URL.

### About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle's strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company's website at [www.eagleus.com](http://www.eagleus.com).

Investor Relations for Eagle Pharmaceuticals, Inc:

Lisa M. Wilson

T: 212-452-2793

E: [lwilson@insitecony.com](mailto:lwilson@insitecony.com)